Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: aurothioglucose, motexafin gadolinium, arsenic trioxide | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 593 | 0.79 |
| pathways Reactome | 8 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 5647
Sealed predictions
- TXNRD1 in dopamine neurons, braak+0.26 (p 0.499) → +0.47 (p 0.199)receipt 5655
Swarm cases
receipt 5655: TXNRD1 in dopamine neurons, braak
- power
- full sample +0.32 (p 0.201, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.109, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.099, n 18). could be the mix.
- skeptic
- leave-one-out range +0.22 to +0.44, sign flips 0; without severely affected donors +0.32 (p 0.201, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TXNRD1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts